Today Inversago Pharma Inc., a preclinical-stage biotech company developing new CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of Dr. Caroline Fradette as Vice-President, Clinical Research.
“Over its first year of operations, Inversago has steadily progressed its programs towards the clinic”, highlighted François Ravenelle, PhD, CEO of the Company. “As part of our transition from a preclinical to a clinical stage company, we are thrilled to welcome Caroline to our team to head our clinical research programs. Caroline brings experience and a comprehensive set of skills that will improve our development strategy”, added Dr Ravenelle.
“I am delighted to join Inversago at such an exciting stage of the CB1 blocker comeback, and I look forward to working with the team and lead this important clinical program in the coming years”, said Dr Fradette.
About Dr. Caroline Fradette
Caroline Fradette, PhD, has more than 15 years of clinical research experience gained in several pharmaceutical organizations, with a rapid growth of responsibilities. In her most recent position as Director, Clinical Research at ApoPharma, she headed a team of 25 individuals, handling several concurrent clinical trials from Phase 1 to Phase 4. Dr Fradette holds a PhD in Pharmacology from Université de Montréal.
About Inversago Pharma
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated to first generation CB1 blockers, allowing the company to exploit their full medical potential. For more information, visit www.inversago.com.